After observing low mRNA encapsulation in EVs after electroporation, researchers engineered a plasmid to transfect HEK-293 cells, resulting in the secretion of EVs enriched with prodrug-encoding mRNA to treat HER2+ breast cancer, improving upon electroporation loading strategies mentioned previously 116. The gene discussed is ERBB2; the disease is breast carcinoma.